Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1965; 13(02): 305-313DOI: 10.1055/s-0038-1656232 Originalarbeiten — Original Articles — Travaux Originaux Schattauer GmbH SchattauerSurvival of Transfused Factor X in Patients with Stuart Disease[*] RobertsAuthors Author Affiliations H. R Roberts 1 Departments of Pathology and Medicine, University of North Carolina, Chapel Hill, North Carolina, U.S.A. E Lechler 1 Departments of Pathology and Medicine, University of North Carolina, Chapel Hill, North Carolina, U.S.A. W. P Webster 1 Departments of Pathology and Medicine, University of North Carolina, Chapel Hill, North Carolina, U.S.A. G. D Penick 1 Departments of Pathology and Medicine, University of North Carolina, Chapel Hill, North Carolina, U.S.A. Recommend Article Abstract Buy Article(opens in new window) Summary These studies show that the intravascular “half-life” of transfused factor X may vary in a single subject from 20% to 42 hours with an average of 32½ hours. Recent previous transfusions into patients with Stuart factor deficiency seem to alter the survival curves of transfused factor X. Extra vascular diffusion of intravascular factor X does occur as demonstrated by appearance of this factor in the lymph of a patient with Stuart disease following transfusion of normal plasma. Apparently the disappearance of factor X is a function of at least two variables; that of extravascular distribution and metabolic destruction. However, factors other than extravascular diffusion may be operative during the accelerated first phase of disappearance. Full Text References References 1 Aggeier P. M. Physiological basis for transfusion therapy in hemorrhagic disorders: A critical review. Transfusion 1: 71 1961; 2 Hougie G, Barrow E. M, Graham J. B. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called “Stable Factor” (SPCA, Proconvertin, factor VII) deficiency. J. clin. Invest. 36: 485 1957; 3 Williams J. A, Fine J. Measurement of blood volume with a new apparatus. New Engl. J. Med. 264: 842 1961; 4 Hoag S, Aggeler P. M, Fowell A. H. Disappearance rate of concentrated proconvertin extracts in congenital and acquired hypoproconvertinemia. J. clin. Invest. 39: 554 1960; 5 Averette H. E, Hudson R. G, Viamonte Jr. M. I, Parks R. E, Ferguson J. H. Lymphangio-adenography (lymphography) in the study of female genital cancer. Cancer 15: 769 1962; 6 Graham J. B. Stuart clotting defect and Stuart factor. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 4: 22 1959; 7 Duckert F. On the properties of Stuart-Prower factor. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 4: 32 1960; 8 Biggs R, Derisori K. W. E. The fate of prothrombin and Factors Vili, IX, and X transfused to patients deficient in these factors. Brit. J. Haemat. 9: 532 1963; 9 Brinkhous K. M, Walker S. A. Prothrombin and fibrinogen in lymph. Amer. J. Physiol. 132: 666 1941;
